8-K: Inspire Medical Systems Announces Strong Preliminary Q2 Results and Raises Full Year Revenue Guidance

Inspire Medical Systems reported preliminary unaudited second-quarter revenue of $195.9 million, a 30% increase year-over-year, and raised its full-year 2024 revenue guidance to $788-$798 million.

Summary

• Inspire Medical Systems announced preliminary unaudited results for the second quarter of 2024, showing strong revenue growth.
• Second-quarter revenue is expected to be $195.9 million, a 30% increase compared to the same quarter in 2023.
• U.S. revenue is anticipated to be $187.8 million, also a 30% increase year-over-year.
• Revenue outside the U.S. is expected to reach $8.1 million, a 27% increase compared to the second quarter of 2023.
• The company has updated its full-year 2024 revenue guidance to a range of $788 million to $798 million.
• This new guidance represents a 26% to 28% growth over the full year 2023 and is a $13 million increase from the initial 2024 revenue guidance range of $775 million to $785 million.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong revenue growth, increased guidance, and confident management commentary. The risks mentioned are standard for a company in this sector and do not detract from the overall positive tone.

Positives

• The company experienced strong revenue growth in the second quarter of 2024.
• Both U.S. and international revenue saw significant year-over-year increases.
• The company has increased its full-year revenue guidance, indicating confidence in continued growth.
• The company's CEO highlighted strong execution and revenue performance in the second quarter.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• These risks include market acceptance of their therapy, competition, regulatory actions, and macroeconomic trends.
• The company's ability to achieve and maintain adequate levels of coverage or reimbursement for their system is a risk.
• The company is dependent on third-party suppliers, contract manufacturers and shipping carriers.
• The company's ability to manage growth and expand its sales and marketing organization is a risk.

Future Outlook

The company anticipates continued strong revenue growth in the second half of 2024 and has increased its full-year revenue guidance to $788-$798 million.

Management Comments

• We are so proud of our teams strong execution and revenue performance in the second quarter, which showed sequential revenue growth acceleration in the U.S., said Tim Herbert, Chairman and CEO of Inspire.
• With the strong momentum we are seeing in our business, we have increased confidence regarding strong continued revenue growth in the second half of 2024.
• As a result, we are increasing our revenue guidance to $788 million to $798 million for full year 2024.

Industry Context

This announcement indicates strong performance in the medical technology sector, particularly in the area of sleep apnea treatment, and suggests that Inspire is gaining market share and experiencing increased adoption of its therapy.

Comparison to Industry Standards

• While specific competitor results are not provided in this document, a 30% year-over-year revenue growth in the medical device industry is generally considered very strong.
• Companies like ResMed (RMD) and Philips (PHG), which also operate in the sleep apnea space, are key comparators, though their specific growth rates and product offerings differ.
• Inspire's focus on neurostimulation therapy for sleep apnea is a unique approach compared to traditional CPAP machines, which may contribute to its higher growth rate.
• The updated revenue guidance suggests that Inspire is outperforming initial expectations and is on track for significant growth in 2024.

Stakeholder Impact

• Shareholders are likely to react positively to the strong revenue growth and increased guidance.
• Employees may be motivated by the company's success and positive outlook.
• Customers may benefit from the company's continued innovation and expansion of its therapy.
• Suppliers and partners may see increased business opportunities due to the company's growth.

Next Steps

• The company plans to report full Q2 results and host an earnings conference call on August 6, 2024.

Key Dates

Keywords

Inspire Medical Systems, obstructive sleep apnea, revenue, medical technology, neurostimulation, financial results, revenue guidance